GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
V

Vaxxinity VAXX · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.03

+24900.00%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Vaxxinity — daily VAXX Delayed
Market value
$3.2m
Last close × shares
Volume
257
Shares, 9 Nov 2026

About Vaxxinity

Its shares trade under the ticker VAXX. It has been listed since 11 November 2021. In the fiscal year to 31 December 2022, it reported revenue of −$1,000 and a net loss of $75.2m. At that date it held total assets of $106.4m and shareholders' equity of $62.2m.

Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company is headquartered in Dallas, Texas. The company went IPO on 2021-11-11. The firm is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat chronic disorders and infectious diseases with large patient populations and unmet medical needs. The Company’s synthetic peptide vaccine platform (Vaxxine Platform) has enabled the innovation of pipeline candidates designed to bring the efficiency of vaccines to the treatment of chronic diseases, including Alzheimers, Parkinsons, migraine, and hypercholesterolemia. Its pipeline consists of six programs, which include UB-311, UB-312, VXX-301, UB-313, VXX-401 and UB-612. Its UB-311 targets toxic forms of aggregated amyloid-b (Ab) in the brain to fight AD. Its UB-312 targets toxic forms of aggregated a-synuclein in the brain to fight PD and other synucleinopathies, such as Lewy body dementia (LBD) and multiple system atrophy (MSA). Its UB-313 targets Calcitonin Gene-Related Peptide (CGRP) to fight migraines.

Figures and description from our data supplier, not checked against the company's own report.

More about Vaxxinity →

Latest on Vaxxinity

Our reporting

We have not reported on Vaxxinity yet.

Next results

11 Nov 2026

Due on 11 Nov 2026. Analysts expect earnings of -0.12 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Vaxxinity's ticker?

Vaxxinity trades as VAXX on its US listing, under ISIN US92244V1044.

What was Vaxxinity's last closing price?

0.03 on 9 Nov 2026. The figure is in USD and is never converted.

When does Vaxxinity next report results?

Results are expected on 11 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.